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1. Introduction 
Ankle osteoarthritis (OA) is a degenerative joint disease that can cause substantial pain, 
muscle weakness and functional limitations. Due chiefly to its post-traumatic origin and 
appearance in young patients, ankle OA has a high impact on socioeconomics and patients’ 
quality of life. Approximately 6% to 13% of all cases of OA involve the ankle joint (Thomas 
and Daniels, 2003). Recent research also identify that a larger number of patients are being 
diagnosed with ankle OA (Saltzman et al, 2005). Currently, no curative therapy is available 
for OA, and thus the overall goals of management are to reduce pain and prevent disability. 
Treatment options include simple analgesics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), weight reduction, physical and occupational therapy, activity modification, 
orthotic devices, shoe modifications, intraarticular corticosteroid injections, and surgery. 
Although some cases can be treated successfully with surgery, many patients are either not 
good candidates for surgery or may want to avoid or delay it if possible. There is a need for 
a treatment that reduces chronic joint pain and improves function yet avoids toxic effects of 
medications and the morbidity and mortality risks of surgery. One such option for these 
patients may be the intraarticular injection of hyaluronate. 
Hyaluronate, a high molecular weight polysaccharide, is a principal component of synovial 
fluid and extracellular matrix of articular cartilage. It contributes to the elasticity and 
viscosity of synovial fluid. In addition to providing joint lubrication and shock absorbancy, 
hyaluronate helps to maintain the structural and functional characteristics of the cartilage 
matrix. It also inhibits the formation and release of prostaglandins, induces proteoglycan 
aggregation and synthesis, and modulates the inflammatory response (Frizziero, 1998). In 
OA, the concentration and molecular weight of hyaluronate are reduced, limiting its role in 
maintaining normal joint biomechanics (Engström-Laurent A, 1997). Viscosupplementation 
with intraarticular injections of hyaluronate was approved by the Food and Drug 
Administration (FDA) in 1997 for treating pain associated with knee OA. Although the exact 
mechanism of action is not understood with certainty, recent research suggests that it exerts 
anti-inflammatory, analgesic, anabolic and possibly chondroprotective effects on the 
articular cartilage and joint synovium that reduce pain and disability and improve joint 
function. 
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There are five injectable forms of hyaluronate approved for use in the United States, 
including Hyalgan, Supartz, Orthovisc, Synvisc and Euflexxa (Table 1). Each of these 
hyaluronate products differ in their origin, method of production, molecular weight, 
dosing instructions, rheologic properties, cost, pharmacodynamics and possibly clinical 
outcomes.  
 
Trade name Hylagan Synvisc Supartz Orthovisc Euflexxa 
generic name 
sodium 
hyaluronate 
hylan G-F20 
 sodium 
hyaluronate 
high molecular 
weight 
hyaluronan 
sodium 
hyaluronate 
Year Approved 1997 1997 2001 2004 2004 
Source 
Rooster combs 
(naturally 
derived) 
Rooster combs 
(chemically 
modified, or 
cross-linked) 
Rooster combs 
(naturally 
derived) 
Rooster combs 
(naturally 
derived) 
Bacterial 
fermentation 
(naturally 
derived) 
Molecular 
Weight 
(kd) 
500-730 6000 620-1170 1000-2900 2400-3600 
Amount  
per injection 
2 ml 2 ml 2.5 ml 2 ml 2 ml 
Active 
ingredients per 
injection 
20mg sodium 
hyaluronate 
16mg sodium 
hyaluronate 
derivative 
25mg sodium 
hyaluronate 
30mg sodium 
hyaluronate 
20mg sodium 
hyaluronate 
Number of 
injections per 
cycle 
3 or 5 weekly 
3 weekly 
(In 2009, FDA 
approved single-
dose Synvisc-
One™ 6 mL 
injection for the 
treatment of knee 
OA) 
5 weekly 3 or 4 weekly 3 weekly 
Table 1. Characteristics of five formulations of intraarticular Hyaluronans available in the 
United States 
All products are manufactured from rooster combs except for Euflexxa, which is the only 
non-avian derived hyaluronan approved in the United States. Also, Synvisc undergoes 
additional chemical crosslinking to create hylans with increased molecular weight and 
increased elastoviscous properties. The differing molecular weights of the products lead 
to different half-lives; the half-life of Hyalgan or Supartz is estimated at 24 hours, while 
the half-life of Synvisc may range up to several days. There is no consistent evidence from 
well-controlled clinical studies that documents the superior efficacy of one product over 
another. 
Although viscosupplementation is a well-established treatment option in knee OA and is 
included in the professional guidelines by European League of Arthritis & Rheumatism 
(EULAR) and American College of Rheumatology (ACR), evidence regarding its use in 
ankle OA is limited. Recently, several studies attempting to evaluate the use of hyaluronate 
in the ankle have been published. In this chapter, we discuss our experiences, the 
indications, injection technique and review the clinical outcomes on hyaluronate use in 
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patients with ankle OA. Additionally, future directions for the use of hyaluronate in the 
management of ankle OA and areas of active research in hyaluronate are discussed. 
2. Indications 
The exact indications for viscosupplementation are still evolving, but it currently can be 
considered for use in patients who have significant residual symptoms despite traditional 
nonpharmacologic and pharmacologic treatments. In addition, patients who have 
gastrointestinal or renal intolerance to NSAIDs, and those who wish to postpone surgical 
intervention or are poor candidates for surgery can be considered for these injections. 
Contraindications to hyaluronate injection include protein/avian allergy (except Euflexxa), 
active skin disease and joint infections at the injection site. Patients with substantial venous 
or lymphatic stasis in the legs, bleeding disorder or treatment with anticoagulants are 
relatively contraindicated. Hyaluronate is not recommended to pregnant women, lactating 
women and children under 18, because the safety and effectiveness have not been 
established.  
The ideal candidate for viscosupplementation has yet to be defined. Studies are inconclusive 
regarding the best responders with respect to age, level of OA as defined radiographically, 
level of symptoms and level of physical activity. We previously reported (Sun et al, 2006a) 
that patients with Kellgren-Lawrence grade 1and 2 ankle OA had good response to 
viscosupplementation (grade 1, doubtful narrowing of joint space and possible osteophytic 
lipping; grade 2, definite osteophytes and possible narrowing of joint space). This suggested 
that viscosupplementation was effective in mild to moderate ankle OA. Whether severe 
cases would likely respond to viscosupplementation remained unknown. In another case 
series by our study group (Sun et al, 2011), we stratified patients by age and radiographic 
severity to determine whether these factors would influence the treatment response. 
Subgroup analysis results showed that there was no significant difference in outcomes 
between patients with grade 2 and grade 3 OA in each study period. However, we found 
difference in clinical balance tests between patients of the younger age-group and the older 
age-group at different time points. As the subgroup analysis was not sufficiently powered, 
definite conclusion could not be drawn.  
As the treatment group increases, the ideal subgroup of patients who are best candidates for 
ankle viscosupplementation should be identified. 
3. Injection technique  
In our experience, intraarticular injection of the ankle joint is easy to perform and requires 
no radiologic guidance. The two approaches for performing an ankle joint injection are the 
anterior medial and anterior lateral (Figure 1). For the anterior medial approach, we position 
the patient in the supine position, with the knee flexed and the foot flat on the examination 
table. The ankle is placed in a degree of plantarflexion, which opens the anterior aspect of 
the joint. We identify the space between the anterior border of the medial malleolus and the 
medial border of the tibialis anterior tendon and palpate this space for the articulation of the 
talus and tibia to locate a suitable entry point into the ankle joint. The injections are 
performed in aseptic conditions. We insert a 21-23 gauge needle into the identified space 
and direct posterolaterally to run parallel to the upper surface of the talus, which is slightly 
convex . Joint effusion, if present, should be aspirated before injection. Alternatively, the 
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anterior lateral approach is done with the patient positioned with the foot in plantar flexion. 
The needle is inserted from the anterior lateral position and directed posteriorly toward the 
medial malleolus. The needle is advanced until there is a drop in tissue resistance 
confirming entry into the joint. Excessive weight bearing and strenuous activity are 
discouraged within 2 days following injection. Otherwise, no specific post-injection 
instructions are necessary. 
Most injection in the ankle joint was performed without any instrumental guide in the 
literature. One of the limitations of hyaluronate therapy is that it can be difficult to ensure 
that intraarticular injections are actually given into the joint capsule. In clinical trials with 
ankle viscosupplementation, only one trial used a fluoroscopic guide for the injection 
(Cohen et al, 2008). Ultrasound has been used to guide hyaluronate injection in hip and 
hand OA, however, no ultrasound guide has been used in ankle OA studies. The aim for the 
future is to encourage the ultrasound-guided intraarticular injection because it is simple, 
fast, economic and safe; it does not require the use of contrast, allowing the intraarticular 
injection in patients intolerant to iodized contrasts. It can be repeated without limits, allows 
an easy visualization of fluid in the articular recess, the correct position of the needle and the 
distance from the vessels. 
 
 
Fig. 1. The two approaches for ankle joint injection: the anterior medial and anterior lateral 
approaches 
4. Overview of clinical outcomes 
The potential for treating ankle OA by viscosupplementation has been suggested in the 
literature. To date, there are only 3 randomized controlled, double-blind trials ( Salt et al, 
2006; Cohen et al , 2008; Karatosun et al, 2008) (Table 2) and a few case series in the search of 
the literature on viscosupplementation therapy for ankle OA (Table 3). Two recent reviews 
(Migliore et al, 2011; Sun et al, 2009) have provided an overview of clinical trials with 
hyaluronate therapy in ankle OA.  
Salk et al. performed the first randomized, double-blind, saline solution-controlled trial in 
patients with grade 2, 3 and 4 (Kellgren–Lawrence) ankle OA (Salk et al, 2006), assessing the 
efficacy and safety of hyaluronate for the treatment of ankle OA. Patients were randomized 
to receive 5 weekly intraarticular injections of either 1 mL of sodium hyaluronate (10 
mg/mL) or 1 mL of phosphate-buffered saline solution into the ankle joint. The primary 
outcome measure was the ankle osteoarthritis score (AOS) pain and disability assessment 
(Domsic and Saltzman, 1998). At 6-month follow-up, trends toward greater improvement in 
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the hyaluronate group compared with sham injection control were noted. The benefit with 
hyaluronate in the treatment of ankle OA is consistent with previous published studies 
using hyaluronate in the knee.  
 
 
 
 
 
Author Year Viscosupplement Study Patients
Outcome 
Measures 
Outcomes 
Salk et al 
(2006) 
Hyalgan (5 
injections), 
1ml per injection 
17 
9 HA 
8 placebo 
AOS, 
WOMAC pain 
domain, 
Ankle ROM, 
Quality of life,  
Rescue analgesic 
consumption 
Safe and effective at 6 
months in patients 
with  Kellgren-
Lawrence grade 2-4 
ankle OA 
Cohen MM 
et al (2008) 
Hyalgan (5 
injections), 
2ml per injection 
30 
15 HA 
15 placebo 
(saline control)
AOS, 
WOMAC, 
Patient global 
assessment,  
SF-12 (short 
form-12) 
Safe and effective for 3 
months 
Karatosun et 
al (2008) 
Adant (3 
injections), 
2.5 ml per injection
30 
15 HA 
15 progressive 
ankle exercise 
AOFAS 
ankle/hindfoot 
score, 
Gait quality, 
VAS 
No statistical difference 
between the exercise 
and HA injection 
groups in patients with 
Kellgren-Lawrence 
grade 3 ankle OA at 12 
months.  
 
 
 
 
 
Abbreviations in the table: 
HA=hyaluronic acid 
AOS= ankle osteoarthritis score 
AOFAS= American Orthopaedic Foot and Ankle Society 
VAS= visual analog scale 
WOMAC= Western Ontario and McMaster Universities Arthritis Index 
Table 2. Randomized controlled trials of Viscosupplementation in the Treatment of Ankle 
Osteoarthritis 
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Author Year Viscosupplement Study Patients
Outcome 
Measures 
Outcomes 
Sun et al 
(2006) 
Artz (5 injections), 
2.5 ml per injection
75 
75 HA 
N0 placebo 
AOS, 
AOFAS 
ankle/hindfoot 
score, 
Ankle ROM, 
Patients’ global 
satisfaction, 
Rescue 
analgesics 
consumption 
Safe and efficacious, 
effects rapid at 1 week 
post the fifth injection, 
lasting for 6 months  in 
patients with  Kellgren-
Lawrence grade 1 or 2 
ankle OA. 
High patients’ 
satisfaction rate.  
Significant reduction in 
analgesics consumption 
Witteveen 
AGH et al 
(2008) 
Sinvisc  
(1 injections), 
2 ml per injection 
51 one 
injection 
24 2nd injection 
after 1-3 
months 
VAS, 
AOS, 
SF-36 
Safe and effective for 6 
months in patients with 
grade 2 ankle OA (van 
Dijk et al scale).  
Carpenter  
et al (2008) 
Sinvisc (3 
injections), 
2 ml per injection 
26 
14 HA post 
ankle 
arthroscopy  
12 ankle 
arthroscopy  
VAS 
The mean pain score of 
the HA+arthroscopy 
group was 1, the score 
for the arthroscopy  
alone group was 3 on a 
10 point VAS scale in 
patients with Kellgren-
Lawrence grade 2-4 
ankle OA at 3 months, 
with significant 
difference. 
Luciani  
et al (2008) 
Sinvisc  
(3 injections), 
2 ml per injection 
21 
21 HA 
N0 placebo 
AOS 
Significant 
improvement in AOS 
from baseline in 
patients with Kellgren-
Lawrence grade 2 ankle 
OA after 6 months, 
effect  maintained at 12 
and 18-month follow-
ups 
Mei-Dan  
et al. (2010) 
Adant (5 
injections) 
2.5 ml per injection 
13 
13 HA 
N0 placebo 
VAS, 
AOFAS 
ankle/hindfoot 
score, 
Ankle ROM 
Improvement of 20% in 
the ROM, significant 
reduction in VAS scale 
and ankle-hindfoot 
scores in patients with 
Kellgren-Lawrence 
grade 2-4 ankle OA for 7 
months 
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Author Year Viscosupplement Study Patients
Outcome 
Measures 
Outcomes 
Sun et al 
(2011) 
Hyalgan  
(3 injections), 
2 ml per injection 
46 
46 HA 
N0 placebo 
AOS, 
AOFAS 
ankle/hindfoot 
score, 
Ankle ROM, 
4 balance tests, 
Patients’ global 
satisfaction, 
Rescue analgesic 
consumption 
Safe and effective, 
improve physical 
function and balance 
with high patients’ 
satisfaction in patients 
with unilateral 
Kellgren-Lawrence 
grade 2 or 3 ankle OA. 
Abbreviations in the table: 
HA=hyaluronic acid 
AOS= ankle osteoarthritis score 
AOFAS= American Orthopaedic Foot and Ankle Society 
ROM=range of motion 
VAS= visual analog scale 
Table 3. Case Series of Viscosupplementation in the Treatment of Ankle Osteoarthritis 
Cohen et al. performed a randomized, double blind, saline solution-controlled trial of 
patients with grade 2, 3 and 4 (Kellgren–Lawrence) ankle OA (Cohen et al, 2008). Patients 
were randomized to receive 5 weekly injections of either 2 mL of sodium hyaluronate 
(Hyalgan) or 2 mL of phosphate-buffered saline solution in the ankle joint. All injections 
were fluoroscopically guided. The primary endpoint was pain on movement and weight 
bearing using the AOS 3 months after injection. At month 3, the patients in the hyaluronate 
group showed a significant improvement from baseline in AOS total score than those in the 
control group.  
Karatosun et al. performed a prospective randomized trial with 12-months follow-up, to 
evaluate the efficacy of intraarticular injection of sodium hyaluronate (Adant®) 
compared with exercise therapy (Karatosun et al, 2008). Patients with grade 3 (Kellgren–
Laurence) ankle OA were randomized to receive 3 weekly intraarticular injections of 
hyaluronate or an exercise cycle therapy, which included a series of progressive, 
isometric, isotonic range of motion, resistance, closed kinetic chain and proprioceptive 
exercise, for 6 weeks. Outcomes, including the American Orthopaedic Foot and Ankle 
Society (AOFAS) Ankle-Hind Foot score(Kitaoka et al,1994), gait, pain with VAS scale 
were evaluated and analyzed. At 12 months, both groups improve in pain score, walking 
surface, gait quality and total ankle–hind foot score. The authors concluded that the 
patients benefit either by 3 injection of hyaluronate or by 6 weeks of exercise therapy. 
The advantage of exercise therapy may be its non-invasive nature being preferred by 
both the physicians and the patients; however, while exercise therapy last 6 weeks, 
hyaluronate injections stop at 3 weeks. This point may be an advantage for the 
preference of hyaluronate injections. 
In a relatively large case series by our group (Sun et al, 2006a), we reported outcomes of 75 
patients with unilateral grade 1 or 2 (Kellgren–Lawrence) ankle OA. We concluded similarly 
that a regimen of 5 weekly intraarticular injection of sodium hyaluronate was safe and 
effective in the areas of pain and ankle function. Patients expressed a high level of 
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satisfaction, with only relatively few local adverse events. These effects were rapid at 1 week 
post the fifth injection and could last for 6 months. One limitation in this trial includes the 
absence of a control group, thus the placebo effects associated with joint injections per se 
were not analyzed.  
In the prospective case series by Witteveen et al, patients with symptomatic grade 2 (van 
Dijk et al scale) ankle OA (>50 and <90 mm on a 100 mm visual analog scale (VAS), were 
treated with intraarticular injection of Hylan GF-20 (Synvisc, 2 mL) plus an optional second 
injection if pain remained at baseline level after 1, 2 or 3 months, with 6–9-months follow-up 
period (Witteveen et al, 2008). The primary efficacy endpoint was the change from baseline 
in the Pain VAS Score at 3 months. The results showed a statistically significant decrease in 
the mean Pain VAS score from 68.0 mm at baseline to 33.8 mm at month 3. They reported 
that a regimen of one single intraarticular injection of hyaluronate (Synvisc), with the option 
of a second injection after 1–3 months if pain relief is inadequate, is an efficacious treatment 
of patients with symptomatic ankle OA.  
Carpenter et al. conducted a controlled trial investigating the effectiveness of Hylan G-F 20 
in reducing pain following ankle arthroscopy in patients with grade 2, 3 and 4 (Kellgren–
Laurence) ankle OA (Carpenter and Motley, 2008). Fourteen patients received 3 weekly 
injections of Hylan G-F 20 post ankle arthroscopy, while 12 patients received only ankle 
arthroscopy. At 3 months, the mean pain score of the Hylan G-F 20 plus arthroscopy group 
was 1, while the score for the arthroscopy alone group was 3 on a 10 point VAS scale, and 
this difference was statistically significant.  
In a case series by Luciani et al, 21 patients with a grade 2 (Kellgren–Laurence) ankle OA 
had 3 weekly intraarticular injections of 2 ml of synvisc into the ankle joint (Luciani et al, 
2008). The primary clinical outcome measurement was the AOS. The results showed 
significant improvement of the AOS from baseline after 6 months and this improvement 
was maintained at 12- and 18-month follow-ups.  
Mei-Dan et al. have studied 16 patients with grade 2-4 (Kellgren-Lawrence) ankle OA who 
received intraarticular injections of 25mg of sodium hyaluronate for 5 consecutive weeks 
(Mei-Dan et al, 2010). There was a significant reduction in pain assessed by VAS scale and 
ankle-hindfoot scores and an improvement of 20% in the range of motion. 
Previous ankle viscosupplementation studies reported that five weekly intraarticular 
injections of hyaluronate were safe and effective; however, the effect of three weekly 
injections has rarely been investigated. Our study group (Sun et al, 2011) conducted another 
prospective case series with a 6-month follow-up period and reported that three weekly 
injections of sodium hyaluronate are well tolerated, can provide pain relief, improve 
function and balance in patients with unilateral grade 2 or 3 (Kellgren–Lawrence) ankle OA. 
OA remains by far the most common disease of joints and represents a huge burden to 
society in terms of personal suffering and health resource utilization. The three-injection 
regimen may possibly represent a cost-saving therapy. Besides, pain associated with ankle 
OA may cause loss of balance, leading to falls, more injuries and higher costs to the patient 
and society. This study was the first that examined the effect of hyaluronate on balance in 
patients with ankle OA, as we had previously reported significant improvements in pain, 
physical function and balance tests after five weekly hyaluronate injections in geriatric 
patients with knee OA (Sun et al,2006b). Although the mechanism by which hyaluronate 
results in a clinical benefit in balance remains unknown and it remain an area important for 
future research, we thought pain reduction might be one of the major contributing factor.   
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5. Complications 
Because use of hyaluronate in the ankle is an “off label” application of this agent, patient 
safety is a key issue considering this treatment. Clinical studies have demonstrated that 
viscosupplementation is generally safe and well tolerated. Although significant 
complications are rare, mild adverse effects have been reported. Because there are no 
known hyaluronate–medication interactions, it is a good option for patients on multiple 
medications, particularly the elderly. Mild injection-site pain and swelling are the most 
common adverse events in the injected joints. These reactions are usually transient, 
resolving without intervention within 1 to 3 days. Other adverse events included rash, 
muscle cramps, dizziness, nausea, headache, local ecchymosis and pruritus. The overall 
incidence of adverse reactions in knee studies has been reported to be approximately 1% 
to 4%. Rare cases of post-injection pseudogout with sodium hyaluronate and Synvisc have 
been reported. It is unclear whether these reactions were caused by the hyaluronate itself 
or by the injection procedure. There is growing evidence that Synvisc may be associated 
with an adverse event termed pseudosepsis or a severe acute inflammatory reaction. 
Pseudosepsis presents as severe inflammation of the joint, with a large effusion, and 
significant pain occurring within 1 to 3 days post injection. It requires symptomatic 
treatment, including use of modalities, activity modification, analgesics, and NSAIDs. 
Once infection has been excluded, intraarticular steroids may be of value. Despite a lack 
of understanding of both the etiology of pseudosepsis and the long-term effects of these 
local immunological reactions, such events would be expected to incur additional 
socioeconomic costs. Additional study is required to enable the treating physician to 
identify patients at risk for this injection related complication and to determine whether 
patients with a history of a pseudosepsis after hyaluronate injection can safely receive 
further hyaluronate therapy. 
The safety in the treatment of ankle OA appears to be similar to the injections widely 
performed in the treatment of knee OA. No systemic adverse events were reported in the 
literature relating to ankle viscosupplementation; however, cases of local adverse 
reactions do exist. In study by Salt et al (Salk et al, 2006), injection site pain was noted in 5 
(29%) of the 17 patients, with no significant difference between the groups. In our case 
series (Sun et al, 2006a), local pain and erythema at the injection site occurred in 5 of 75 
patients, it was mild and resolved within 48 hours without sequela. The adverse reaction 
rate was 5.3% per injection and 6.7% per patient. We observed that these adverse events 
sometimes occurred after several injections without any reaction previously, and 
sometimes they did not occur in subsequent injections. Interestingly, local adverse 
reactions did not predict treatment failure. All of these patient received subsequent 
injections and they still improved clinically and reported high satisfaction. The incidence 
of adverse events was also low in the study by Cohen et al (Cohen et al, 2008), only one 
case of pseudogout, resolved without therapy, was observed in the Hyalgan group. 
Witteveen et al (Witteveen et al, 2008) reported 35 patients (63.6%) experienced a total of 
89 adverse events in their study, which was relatively high compared with other studies. 
The majority of adverse events were arthralgia, injection site pain, and joint swelling, 
which were reported to be mild or moderate in intensity and transient in nature. Luciani 
et al. reported 11 patients (52%) in their case series presented transient pain and erythema 
in the injection site that resolved within 2 days and did not interfere with remaining 
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injections (Luciani et al, 2008). In the case series by Carpenter et al.  (Carpenter and 
Motley, 2008), they did not observe any local or systemic adverse events.  
6. Further studies needed 
Despite the fact that hyaluronate has been proposed as a useful treatment of symptomatic 
knee OA, its role in the treatment of ankle OA is still not clear, due fundamentally to the 
dearth of large, well-controlled studies and to the methodologic limitations of those that 
have been published. Most studies included small cohorts, short follow-up periods and an 
overall level of evidence is low. The clinical effects of the hyaluronate products have 
considerable heterogeneity and therapeutic variability, as most studies use different 
dosages, injection frequencies, different outcome measures, especially at different time 
points.  Conclusions regarding the clinical effectiveness of each hyaluronate product could 
not be drawn. There was no evidence for differential effects according to subgroups defined 
by age, gender, primary/secondary disease, body mass index/weight, or disease severity. 
The exact mechanisms of viscosupplementation action on osteoarthritic joints are uncertain. 
Although recent attention has focused on the disease-modifying potential of hyaluronate, 
especially the chondroprotective mechanism, definitive evidence is still lacking. We believe 
that hyaluronate can be used as an adjunct therapy, after failure of one or more courses of 
oral pain medications, or perhaps as a first choice in the treatment of ankle OA before 
prescription of pain medications.  
Future studies regarding optimal dosing regimen, injection frequency and injection technique, 
optimal number of injections in a course of treatment, favorable prognostic factors, duration of 
benefits, effectiveness and safety of repeated courses of therapy, longer term trials, head-to-
head comparisons of the various hyaluronate products, as well as the biochemical, 
morphologic, and histopathologic effects on cartilage are warranted. Cost-effectiveness needs 
to be addressed. Comparison studies or combination therapies with other treatment options, 
such as intraarticular steroid injections, NSAIDs and therapeutic exercise, are also needed to 
help determine the best overall treatment plan for patients with ankle OA.  
7. Conclusion 
The published data suggest that viscosupplementation may potentially be a safe and 
effective alternative in treating patients with ankle OA. However, there are still inadequate 
data to provide definitive conclusions on the efficacy of hyaluronate in reducing pain or 
improvement of function among patients with ankle OA. The FDA has not approved 
intraarticular hyaluronate for joints other than the knee. To date ankle viscosupplementation 
should only be used under careful supervision by the clinician. Many uncertainties on the 
use of hyaluronate remain. The use of standardized outcome measures is encouraged to 
facilitate meta-analyses and between trial comparisons. Additional studies are required 
before viscosupplementation should be included into the treatment paradigm for patients 
with ankle OA. 
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